Navigation Links
Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd.
Date:5/19/2008

MOUNTAIN VIEW, Calif., May 19 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that Jeffrey S. Williams has rejoined the company in a part-time position as President, Alexza Singapore Pte. Ltd., a wholly owned subsidiary of Alexza. Mr. Williams will have primary responsibilities in managing the Alexza subsidiary in Singapore and establishing potential joint ventures in Singapore. Alexza intends to initiate manufacturing operations for key components of Alexza's single-dose Staccato(R) device in Singapore. Alexza's single-dose Staccato devices are used in a majority of its current product candidates, including its lead program, AZ-004 (Staccato loxapine), which is in Phase 3 clinical testing for the treatment of acute agitation in schizophrenic or bipolar disorder patients.

Mr. Williams will continue to serve as the Chief Business Officer for CoNCERT, Pharmaceuticals, Inc., in a part-time capacity. Prior to his tenure at CoNCERT, Pharmaceuticals, Mr. Williams held senior vice president positions in manufacturing, operations, and corporate/business development for Alexza Pharmaceuticals from March 2004 to November 2007. During 2001 - 2004, Mr. Williams served as Vice President, Corporate Development for Scion Pharmaceuticals, Inc., and Vice President, Corporate Development and Strategy for EmerGen, Inc. Mr. Williams received an M.S. in management from the M.I.T. Sloan School of Management and a B.A. in economics from Brigham Young University.

"We are very pleased to welcome Jeff back to Alexza in this newly created position and as a member of our management team," said Thomas B. King, President and CEO. "Jeff's broad experience will serve us well as we continue to advance our programs towards commercialization."

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in Phase 1 testing include AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza is available online at http://www.alexza.com.

Safe Harbor Statement

Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements.

These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Nastech Pharmaceutical Company Announces the Jeffrey Wenig Memorial Award for Outstanding Achievement in Drug Delivery
2. Neuromed Appoints Jeffrey Arcara and Gene Wright to Senior Management Team
3. James Marsden and Ashley & Jeffrey McDermott to Receive Honors at the Tourette Syndrome Association 2008 Champion of Children Awards Dinner
4. Jeffrey Modell Foundation and Talecris Biotherapeutics Expand Diagnostic Services for Primary Immunodeficiencies at Lucile Packard Childrens Hospital at Stanford
5. Jeffrey J. Grieco Confirmed as USAID Assistant Administrator for Legislative and Public Affairs
6. National Council of Negro Women (NCNW) Partners With Sherwin-Williams to Target Lead Risks in Neglected Housing
7. Statement by Bonnie J. Campbell, Former Attorney General of Iowa and Spokesperson for Atlantic Richfield Co., Millennium Holdings, LLC, NL Industries, Inc., and The Sherwin-Williams Company on the Jury Verdict Reached Today in the Thomas (Milwaukee) Case
8. Pennsylvania Invests $12.5 Million to Kick Off Williamsport Hospital Project
9. Texas Senator Tommy Williams Honored as Champion for Children by the AMERIGROUP Foundation
10. Brad Williams Joins OrthoSynetics(TM) as Director, IT Infrastructure
11. Vanessa Williams and Carmen Marc Valvo Make It Fashionable to Talk About Colon Cancer In New Public Service Announcement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... Hotze ... industry, announces Chris Brandl as its New Guest Director. , Brandl is ... corporations throughout his career. He began his professional career at Omnium Worldwide, now ...
(Date:2/27/2017)... ... February 27, 2017 , ... Much attention has been ... women who become dependent on opioid painkillers has fallen short. From 1999 until 2010, ... a 237% increase in fatal overdoses in male populations.(1) , The proportion of women ...
(Date:2/27/2017)... ... February 27, 2017 , ... Orange County dentist, ... inflammatory gum condition that occurs when the bacteria in plaque infect the gums and ... as a scaling and root planing or SRP, and can include surgical therapies if ...
(Date:2/27/2017)... ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines from the ... studies, the Center for Disease Control ( CDC ) and Infectious Diseases Society of ... Liegner, M.D. has compiled into a single volume a compelling argument that the disease ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair ... announce a new informational post on robotic hair transplantation. San Francisco residents may ... transplant and Follicular Unit Transplantation (FUT) can sound similar. Either treatment can be ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... , Feb. 27, 2017   Royal ... PHIA), a global leader in health technology, today ... Drug Administration (FDA) to market its ElastQ Imaging ... family of ultrasound systems. ElastQ Imaging enables simultaneous ... which is essential for the diagnosis of various ...
(Date:2/27/2017)... PLACENTIA, Calif. , Feb. 27, 2017   ... new line of nutritional supplements using its groundbreaking new ... and 90 percent of potency through digestion per ... nutritional supplements solve the problem of nutritional waste and ... Prevent degradation during digestive processes Improve ...
(Date:2/27/2017)... FORT WASHINGTON, Pa. , Feb. 27, 2017  Impax Laboratories, Inc. (NASDAQ: ... the following upcoming investor conferences. Raymond James ... a.m. ET on March 6, 2017 in Orlando, FL. ... Care Conference at 8:00 a.m. ET on March 7, 2017 in ... at 8:30 a.m.ET on March 16, 2017 in Miami, FL. ...
Breaking Medicine Technology: